Food, drug, insect sting allergy, and anaphylaxisAntihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis
Section snippets
Study design and setting
The study had a retrospective observational cohort design. Patients were consecutively included at the Saint Mary's Hospital ED, a tertiary care academic ED with 72,000 annual patient visits.
Selection of participants
Electronic medical records of ED patients aged 18 years and older were electronically queried. Records of all patients who had any ED diagnosis containing “allerg,” “anaphy,” or “sting” were reviewed, and those who met the National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis
Results
From April 2008 to July 2011, we included 302 adults who met NIAID/FAAN diagnostic criteria for anaphylaxis. Baseline characteristics, suspected triggers of anaphylaxis, underlying lung disease, and outcomes of the study cohort are summarized in Table I. Median age of the study sample was 44.3 years (interquartile range, 31.5-58.0). Two hundred four patients (68%) were female, and 91% were white, reflecting the relatively small proportion of minorities in the community. Eighty-seven (29%)
Discussion
In our cohort we observed that antihypertensive medication use was associated with increased organ system involvement and hospital admission after adjusting for age, gender, suspected trigger, and preexisting lung disease. Although the associations between ACE inhibitors and beta-blockers and anaphylaxis severity have been evaluated previously, our study includes a larger spectrum of potential markers of increased severity and collected data on additional antihypertensive medications.
References (19)
- et al.
Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization
J Allergy Clin Immunol
(2004) - et al.
Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis
Ann Allergy Asthma Immunol
(2008) - et al.
Second symposium on the definition and management of anaphylaxis: summary report–second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
Ann Emerg Med
(2006) Clinical features and severity grading of anaphylaxis
J Allergy Clin Immunol
(2004)- et al.
Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity
J Allergy Clin Immunol
(2009) - et al.
Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade
J Allergy Clin Immunol
(1981) - et al.
Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections
J Allergy Clin Immunol
(1990) - et al.
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Peptides
(2000) - et al.
Plasma bradykinin in angio-oedema
Lancet
(1998)
Cited by (0)
This publication was supported by National Institutes of Health/NCRR/NCATS CTSA grant no. UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Disclosure of potential conflict of interest: S. Lee, E. P. Hess, D. M. Nestler, V. R. Bellamkonda Athmaram, M. F. Bellolio, W. W. Decker, V. Manivannan, S. C. Vukov, and R. L. Campbell have received research support from the National Institutes of Health (NIH). J. T. C. Li has received research support from the NIH and has stock options in Novartis, Abbott, and Johnson & Johnson. J. B. Hagan has received research support from the NIH, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, and MedImmune; was chairman of the Dyax Adjudication panel of KALBITOR; and has held stock in Johnson & Johnson and TEVA in the last 3 years.